×

Sign In

Search
Home

Novo Nordisk plans to start late-stage trials for experimental obesity drug amycretin

By Thomson Reuters Jun 12, 2025 | 12:22 PM

(Reuters) -Novo Nordisk said on Thursday it plans to start late-stage trials of amycretin injection and oral drugs during the first quarter of 2026 for adults who are overweight or obese.

(Reporting by Harshita Meenaktshi in Bengalurulu; Editing by Leroy Leo)

China, ASEAN to submit upgraded free trade deal to leaders in October, says China's foreign minister

New page opened for Turkey following PKK disarmament, Erdogan says

MLB roundup: Yanks bomb Cubs on Cody Bellinger's 3 HRs

Jaguar Land Rover North America recalls about 21,000 US vehicles over torn passenger airbags

Taiwanese rocket fails to achieve Japan's first foreign launch

Soccer-Chelsea's Fernandez warns about 'dangerous' heat at Club World Cup

Privacy Policy
Terms Of Service

Copyright © 2025. All Rights Reserved.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.